(NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

250

Participants

Timeline

Start Date

August 31, 2015

Primary Completion Date

March 6, 2020

Study Completion Date

June 3, 2021

Conditions
Gastrointestinal Stromal Tumors (GIST)Other Relapsed or Refractory Solid Tumors
Interventions
DRUG

Avapritinib

avapritinib tablets

Trial Locations (19)

3000

Leuven Cancer Institute University Hospitals Leuven, Leuven

3015

Erasmus MC Cancer Institute, Rotterdam

10065

Memorial Sloan Kettering Cancer Center, New York

19111

Fox Chase Cancer Center, Philadelphia

20133

Fondazione IRCCS - Istituto Nazinale dei Tumori, Milan

30256

Cancer Treatment Centers of America, Atlanta

33136

Sylvester Comprehensive Cancer Center, Miami

45122

University of Duisburg-Essen, Essen

69008

Centre Leon Berard, Lyon

77030

MD Anderson Cancer Center, Houston

85258

Scottsdale Healthcare Hospitals DBA HonorHealth, Scottsdale

90403

Sarcoma Oncology Center, Santa Monica

94805

Institut Gustave Roussy, Paris

97239

Oregon Health and Science University, Portland

02215

Dana Farber Cancer Institute, Boston

02-781

Centrum Onkologii-Instytut im. Marii Skłodowskiej-Curie w Warszawie, Warsaw

05505

Asan Medical Center, Seoul

08305

Vall d' Hebron Institute of Oncology (VHIO), Barcelona

SW3 6JJ

Royal Marsden Hospital, London

All Listed Sponsors
lead

Blueprint Medicines Corporation

INDUSTRY